Ensysce Biosciences, Inc. (ENSC)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 65/100 (HIGH), 0.7 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 8.22% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA
- Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation
- Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs
- Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation
- Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study
- Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium
- ENSC Sets Itself Up Nicely for Critical Stage
- Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Ensysce Biosciences, Inc..
Full ENSC Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.